National Bank of Canada
ARQT icon

National Bank of Canada’s Arcutis Biotherapeutics ARQT Stock Holding History

National Bank of Canada’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,071
Closed -$29K – 2851
2025
Q2 		$29K Buy
+2,071
New +$29K ﹤0.01% 2083

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada's ARQT Position: Q3 2025 in Review

National Bank of Canada sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 2,071 shares — an estimated $29K sold.

National Bank of Canada first reported a position in ARQT in Q2 2025 and held it in 1 quarter. The position peaked at $29K in Q2 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • National Bank of Canada reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 2,071 Arcutis Biotherapeutics shares in Q3 2025, an estimated $29K.
  • National Bank of Canada first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • National Bank of Canada's Arcutis Biotherapeutics position peaked at $29K in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.